期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 14, 页码 3394-3401出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1966788
关键词
Acute myeloid leukemia; AML; MDS; venetoclax; transplant
资金
- NCI's Cancer Clinical Investigator Team Leadership Award (CCITLA)
- MSKCC Clinical Scholars T32 Program [2T32 CA009512-31]
- Conquer Cancer Young Investigator Award [GC241610]
- NCI of the National Institutes of Health [P30 CA016359]
- Cancer Center Support Grant/Core Grant [P30 CA008748]
- American Society of Hematology (ASH) Fellow Scholar Award in Clinical Research
The study found that using venetoclax as consolidation therapy before allo-HCT in AML or MDS patients can improve the 12-month survival rate, and venetoclax-based salvage therapy after allo-HCT can provide a potential salvage treatment option with a 12-month survival rate around 43.4%.
The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据